Reading BRTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BRTX free→Reading BRTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BRTX free→QuarterlyIQ Insights · BRTX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . (b) Effective June 11, 2026, pursuant to the Revolving Loan Agreement, Francisco Silva, Nickolay Kukekov and Patrick F. Williams resigned as directors of the Company. (d) On June 12, 2026, pursuant to the Revolving Loan Agreement, the remaining members of the Company’s Board of Directors (the “Board”) appointed Mika Grasso, Katharyn Field and Jati…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . (e) On June 10, 2026, BioRestorative Therapies, Inc. (the “Company”) and Francisco Silva, its Vice President, Research and Development, entered into an employment agreement (the “Employment Agreement”) which provides for a term ending on June 10, 2029. Pursuant to the Employment Agreement, Mr. Silva is entitled to receive an annual salary of $575,…
Entry into a Material Definitive Agreement . On June 10, 2026, BioRestorative Therapies, Inc. (the “Company”) entered into a Revolving Loan Agreement (the “Revolving Loan Agreement”) with Bowery Group LLC (the “Lender”). Pursuant to the Revolving Loan Agreement, the Company may, from time to time and at its sole discretion, request loans (each, a “Loan” and collectively, “Loans”) from the Lender in an aggregate principal amount of up to $1,000,000. Amounts borrowed under the Revolving Loan Ag…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . (e) On May 27, 2026, BioRestorative Therapies, Inc. (the “Company”) and Lance Alstodt, its President, Chief Executive Officer and Chairman of the Board, entered into an employment agreement (the “Alstodt Employment Agreement”) which provides for a term ending on May 27, 2029. Pursuant to the Alstodt Employment Agreement, Mr. Alstodt is entitled to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (f) On May 1, 2026, the Compensation Committee of the Board of Directors of BioRestorative Therapies, Inc. (the “Company”) approved cash bonuses for the Company’s executive officers for the year ended December 31, 2025, as set forth below in the updated Summary Compensation Table. Summary Compensation Table The following Summary Compensation Table…
Result of Operations and Financial Condition. On November 12, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025 (the “Press Release”). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the third quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained in the Pre…
Entry into a Material Definitive Agreement. Subscription Agreements On October 6, 2025, BioRestorative Therapies, Inc. (the “Company”) entered into subscription agreements (the “Subscription Agreements”) with several investors (the “Purchasers”) pursuant to which the Company agreed to sell and issue to the Purchasers an aggregate of 678,125 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), in a registered direct offering at an offering price of $1.60 per share…
Based in part upon the representations of the investors in the Subscription Agreements, the offering and sale of the Unregistered Warrants and the Unregistered Warrant Shares in the Private Placement is being conducted pursuant to an exemption from the registration requirements of the Securities Act provided for in Section 4(a)(2) of the Securities Act and/or Rule 506(b) promulgated thereunder. The Unregistered Warrants and the Unregistered Warrant Shares have not been registered under the Se…
Result of Operations and Financial Condition. On August 12, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025 (the “Press Release”). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the second quarter results. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained in the Press Re…
Result of Operations and Financial Condition. On May 14, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025 (the “Press Release”). The Press Release also provided a business update and included details with regard to the conference call to be held to discuss the first quarter results and business update. A copy of the Press Release is furnished as Exhibit 99.1 hereto. The information contained…
Changes in Company’s Certifying Accountant. (a) Resignation of Independent Registered Public Accounting Firm On November 1, 2024, CBIZ CPAs P.C. acquired the attest business of Marcum LLP (“Marcum”). On April 16, 2025, Marcum informed BioRestorative Therapies, Inc. (the “Company”) that Marcum resigned as the Company’s independent registered public accounting firm. See Item 4.01(b) below with regard to the engagement of CBIZ CPAs P.C. as the Company’s independent registered public accounting f…
Result of Operations and Financial Condition. On March 27, 2025, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing that its financial results for the year ended December 31, 2024 will be released after market close on March 27, 2025 (the “Press Release”). The Press Release included details with regard to a conference call to be hosted by the Company’s management following the release. On the call, the Company’s management will review the financial results and pr…
Importance-ranked changes since the prior daily snapshot.
Valuation fell by 32.8 points (from 42.8 to 10.0).
Management rose by 9.9 points (from 24.5 to 34.4).
risk label changed from 'high' to 'elevated'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.